RAD51 and neoplasm: In olaparib-treated tumor models, the percentage of RAD51-positive cells was 1.25 ± 0.25% in the four PARPi-sensitive models and 66.54 ± 2.70% in the 14 PARPi-resistant models (p < 0.0001).